ReviewVirulence
The challenge of managing fusariosis.
Review in Virulence. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Pooled it
- Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience.Transfusion · 2015Pooled it
- Virulence determinants of Fusarium oxysporum for clinical infections.PLoS pathogens · 2026Article
- Regulation of ABC Transporters and Ergosterol Biosynthesis by the Transcription Factor FvADS-1 Controls Azole Resistance and Virulence inJournal of fungi (Basel, Switzerland) · 2026Article
- Fusariosis in Mexico: cases and gaps to be addressed.Frontiers in cellular and infection microbiology · 2026Review
- Review of Fusariosis in Patients with Hematologic Malignancies.Radiology. Imaging cancer · 2025Review
- New Therapeutic Options for Fusariosis: A Patent Review (2008-2023).Journal of fungi (Basel, Switzerland) · 2025Article
- Allogeneic Hematopoietic Stem Cell Transplantation Despite SevereMicroorganisms · 2025Article
- Acute lymphoblastic leukemia withFrontiers in medicine · 2025Article
- [Fusarium meningoencephalitis in the late puerperium: A case report].Revista medica del Instituto Mexicano del Seguro Social · 2023Article
- The Use of Host Biomarkers for the Management of Invasive Fungal Disease.Journal of fungi (Basel, Switzerland) · 2022Review
- Non-Mucormycetes Causes of Fungal Rhino Sinusitis With Periocular Swelling in COVID-19 With Delta Variant.Cureus · 2022Article
- Multiple Fusarium brain abscesses in a young child.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022Article
- Fungal burn wound infection caused byAnnals of medicine and surgery (2012) · 2021Article
- A rareCurrent medical mycology · 2021Article
- Disinfectants in a Hemodialysis Setting: Antifungal Activity AgainstFrontiers in cellular and infection microbiology · 2021Article
- Prevalence, species distribution, and risk factors of fungal colonization and infection in patients at a burn intensive care unit in Vietnam.Current medical mycology · 2020Article
- Article
- Successful treatment of disseminated fusariosis in a patient with acute lymphoblastic leukemia: A case report and literature review.Medicine · 2019Review
- Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species.Antimicrobial agents and chemotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Fusarium is the second most frequent mold involved in fungal infections and is particularly important among immunocompromised patients. Culture methods and microscopy are still routinely used in clinical laboratories to identify Fusarium spp, and more sophisticated, timely, and effective methods for detecting Fusarium spp. in laboratory samples could improve the outcome of the patient. These investigational diagnostic approaches include serological assays and specific nested PCR assays that can yield positive and negative predictive values of over 90%. Other assays in development, such as mass spectroscopy techniques, can provide accurate and consistent results. The treatment of fusariosis in immunocompromised patients remains a challenge and the prognosis of systemic fusariosis in this population remains poor. Successful treatment is highly dependent on the particular Fusarium species involved in the infection. High dose intravenous amphotericin B formulation is recommended as the first line of therapy in management of fusariosis in patients. Voriconazole is also effective in treating fusariosis. Intolerance, contraindication, or failure of the amphotericin B formulation warrants the use of voriconazole as an alternative agent, and posaconazole is licensed as salvage therapy against invasive fusariosis. Adjunctive therapies such as surgical debridement of infected tissue, granulocyte colony stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating factor (GM-CSF) infusions, or granulocyte transfusions are also tools for managing fusariosis. In conclusion, Fusarium infection is considered an emerging problem and should be suspected in immunocompromised patients experiencing systemic infection and should be treated accordingly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.